Schulthei et al. analyzed TP53 mutations in a total of 228 cases of endometrial carcinomas, including 186 cases of endometrioid carcinomas and 42 cases of serous carcinomas [58]. This evidence concerns the gene TP53 and endometrioid adenocarcinoma.